

ABSTRACT OF THE DISCLOSURE

A method for treating premenstrual dysphoric disorder comprises administering a therapeutically effective amount of a gestagen. Optionally, a natural or synthetic estrogen is also administered. In one embodiment, the gestagen and optional estrogen are administered during the luteal phase of the female menstrual cycle, preferably from day 10 to day 28.

RECORDED BY AUTOMATIC DOCUMENT FEEDER
AT THE U.S. PATENT AND TRADEMARK OFFICE